1. Interleukin‐17 inhibitor, is it safer than tumor necrosis factor inhibitor?
- Author
-
Huang, Jinxian, Zhang, Lijun, and Wei, James C‐C
- Subjects
- *
TUMOR necrosis factors , *PSORIATIC arthritis , *FIBROMYALGIA , *INTERLEUKIN-17 , *ADALIMUMAB , *MEDICAL personnel , *HEPATITIS B , *ANKYLOSING spondylitis - Abstract
The rate of serious infection (1.0% in AS and 1.8% in PsA) and candida infection (0.4% in AS and 0.9% in PsA) remained stable at the fifth year. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Of special interest, candida infections (genital candidiasis, oral candidiasis and candida thrush infection) were reported. The efficacy of IL-17 inhibitor (IL-17i) in inflammatory arthritis (IA) including ankylosing spondylitis (AS) and psoriatic arthritis (PsA) has been ascertained in large-scale clinical trials, while safety, especially infections, should be further addressed and paid more attention to by clinicians in long-term administration. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF